Skip to main content

Table 4 Significantly modified proteins in post treated placebo versus pre treated placebo asthmatic patients

From: Network analysis of quantitative proteomics on asthmatic bronchi: effects of inhaled glucocorticoid treatment

Swiss Prot Acc. No.

Symbol

Entrez Gene Name

Fold Change

Location

Protein Class

P60709

ACTB

actin, beta

-1.66

Cytoplasm

actin and actin related protein

P05783

KRT18

keratin 18

1.31

Cytoplasm

structural protein

P01009

SERPINA1

serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 1

2.34

Extracellular space

serine protease inhibitor

  1. © 2000-2011 Ingenuity Systems, Inc. All rights reserved.
  2. All listed proteins showed a statistically significant difference (p value < 0.05) between the groups using a Student's t-test. The fold change for each protein is calculated by dividing the average ratio of the placebo post treated biopsy with the average ratio of the paired pre placebo biopsy. The negative fold change indicates down regulation of protein expression by placebo, while the positive fold change indicates up regulation by placebo. The cell location of the protein is annotated by IPA. The protein class is determined using the PANTHER Classification System.
Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us